 |
|
|
| |
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure Over 152 Weeks
|
| |
| |
Glasgow 2022 Oct 26
Chloe Orkin1, Jonathan M. Schapiro2, Carlo F. Perno3, Daniel R. Kuritzkes4, Parul Patel5,
Rebecca DeMoor6, David Dorey7, Yongwei Wang5, Kelong Han6, Veerle Van Eygen8, Herta Crauwels8,
Susan L. Ford9, Christine L. Latham5, Marty St. Clair5, Joseph W. Polli5, Simon Vanveggel8,
Kati Vandermeulen8, Ronald D'Amico5, Harmony P. Garges5, Andrew Zolopa5, William R. Spreen5,
Jean van Wyk10, Amy G. Cutrell5
1SHARE Collaborative, Department of Immunobiology, Queen Mary University of London, London, United Kingdom;
2National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel; 3IRCCS Bambino Gesł Pediatric Hospital, Rome, Italy;
4Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States;
5ViiV Healthcare, Research Triangle Park, NC, United States; 6GlaxoSmithKline, Collegeville, PA, United States;
7GlaxoSmithKline, Mississauga, Canada; 8Janssen Research & Development, Beerse, Belgium;
9GlaxoSmithKline, Research Triangle Park, NC, United States; 10ViiV Healthcare, Brentford, United Kingdom
|
| |
|
|
|
|
|
